(Q40013686)

16 September 2017

Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma (English)

1 reference

16 September 2017

3

Toshihiko Torigoe

1 reference

16 September 2017

13

Noriyuki Sato

1 reference

16 September 2017

1

Tomohide Tsukahara

1 reference

16 September 2017

7

Takuro Wada

1 reference

16 September 2017

12

Toshihiko Yamashita

1 reference

16 September 2017

6

Shingo Ichimiya

1 reference

16 September 2017

2

Satoshi Kawaguchi

1 reference

16 September 2017

8

Mitsunori Kaya

1 reference

16 September 2017

9

Satoshi Nagoya

1 reference

16 September 2017

5

Masaki Murase

1 reference

16 September 2017

Shigeharu Kimura

4

1 reference

PubMed ID

18271936

16 September 2017

Takeshi Ishii

series ordinal

10

1 reference

PubMed ID

18271936

16 September 2017

Shin-ichiro Tatezaki

series ordinal

11

1 reference

16 September 2017

1 February 2008

1 reference

16 September 2017

1 reference

16 September 2017

99

1 reference

16 September 2017

2

1 reference

16 September 2017

368-375

1 reference

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

16 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

A quest for therapeutic antigens in bone and soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Future directions for immunotherapeutic intervention against sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Part I: Vaccines for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

A new cellular factor recognizes E2 binding sites of papillomaviruses which mediate transcriptional repression by E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Papillomavirus binding factor (PBF)-mediated inhibition of cell growth is regulated by 14-3-3beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

HLA-restricted specific tumor cytolysis by autologous T-lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Human tumor-specific T lymphocytes: does function matter more than number?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

The human T cell response to melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00695.X

10.1111/J.1349-7006.2008.00695.X

21 January 2018

Identifiers

DOI

1 reference

16 September 2017

1 reference

PubMed ID

18271936